NeuroGenesis Bio

Executive Summary

NeuroGenesis Bio is a clinical-stage cellular therapy company dedicated to developing transformative treatments for neurodegenerative diseases, including progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company's proprietary NG CELL™ platform leverages a unique subpopulation of bone marrow-derived cells to target the underlying causes of central nervous system disorders. Founded in 2007 and headquartered in San Diego, NeuroGenesis Bio aims to provide hope and cures for patients with limited therapeutic options. With a robust scientific foundation and a focus on unmet medical needs, the company is positioned to advance its preclinical programs toward clinical validation, pending regulatory milestones and funding.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for NG CELL Platform in ALS Model60% success
• TBDIND Submission for Leading MS Program40% success
• Q4 2026Strategic Partnership or Licensing Deal for NG CELL Technology35% success